(Finance) – Erfo Pharmaceutical Laboratoryan innovative SME and benefit company operating in the nutraceutical sector, closed the first 9 months of the year with revenues consolidated results of the group which are equal to approximately 4.72 million euros compared to 4.69 million euros in the same period of 2023.
As of 30 September 2024, the adjusted EBITDA generated by the company is equal to approximately 1.07 million euros with a margin equal to 23% of revenues. As of September 30, 2023 there were 1.30 million (28% of revenues).
There NFP adjusted it is cash positive and equal to approximately 2.06 million euros, an improvement compared to 31 December 2023 (1.72 million euros). The data is extremely positive if we consider that, net of the dividend paid in July, the company managed to generate approximately 890 thousand euros in cash with typical management.